首页> 美国卫生研究院文献>PLoS Clinical Trials >MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction
【2h】

MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction

机译:MAP3K19在COPD中过表达,并且是香烟烟雾引起的肺部炎症和下呼吸道破坏的主要介质。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and lung inflammation resulting in a progressive decline in lung function whose principle cause is cigarette smoke. MAP3K19 is a novel kinase expressed predominantly by alveolar and interstitial macrophages and bronchial epithelial cells in the lung. We found that MAP3K19 mRNA was overexpressed in a limited sampling of lung tissue from COPD patients, and a closer examination found it to be overexpressed in bronchoalveolar macrophages from COPD patients, as well as the bronchial epithelium and inflammatory cells in the lamina propria. We further found MAP3K19 to be induced in various cell lines upon environmental stress, such as cigarette smoke, oxidative and osmotic stress. Exogenous expression of MAP3K19 in cells caused an upregulation of transcriptionally active NF-κB, and secretion of the chemokines CXCL-8, CCL-20 and CCL-7. Inhibition of MAP3K19 activity by siRNA or small molecular weight inhibitors caused a decrease in cigarette smoke-induced inflammation in various murine models, which included a decrease in pulmonary neutrophilia and KC levels. In a chronic cigarette smoke model, inhibition of MAP3K19 significantly attenuated emphysematous changes in airway parenchyma. Finally, in a viral exacerbation model, mice exposed to cigarette smoke and influenza A virus showed a decrease in pulmonary neutrophilia, pro-inflammatory cytokines and viral load upon inhibition of MAP3K19. Collectively, these results suggest that inhibition of MAP3K19 may represent a novel strategy to target COPD that promises to have a potential therapeutic benefit for patients.
机译:慢性阻塞性肺疾病(COPD)的特征是持续的气流受限和肺部炎症,导致肺功能的逐步下降,其主要原因是香烟烟雾。 MAP3K19是一种新型激酶,主要由肺中的肺泡和间质巨噬细胞以及支气管上皮细胞表达。我们发现MAP3K19 mRNA在COPD患者的肺组织的有限采样中过表达,并且仔细检查发现它在COPD患者的支气管肺泡巨噬细胞以及固有层的支气管上皮和炎性细胞中过表达。我们进一步发现在环境压力下,例如香烟烟雾,氧化和渗透压力下,MAP3K19在各种细胞系中被诱导。 MAP3K19在细胞中的外源表达引起转录活性NF-κB的上调以及趋化因子CXCL-8,CCL-20和CCL-7的分泌。 siRNA或小分子抑制剂对MAP3K19活性的抑制作用导致在各种鼠模型中香烟烟雾引起的炎症减少,其中包括肺中性粒细胞减少和KC水平降低。在慢性香烟烟雾模型中,对MAP3K19的抑制作用显着减弱了气道实质的气肿变化。最后,在病毒恶化模型中,暴露于香烟烟雾和甲型流感病毒的小鼠在抑制MAP3K19后显示出肺中性粒细胞减少,促炎性细胞因子和病毒载量减少。总体而言,这些结果表明,抑制MAP3K19可能代表一种靶向COPD的新策略,有望对患者产生潜在的治疗益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号